الإحصائيات الأساسية
| CIK | 1737995 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Sharps Technology, Inc.
SEC Filings (Chronological Order)
توفر هذه الصفحة قائمة كاملة ومرتبة ترتيبًا زمنيًا لتصريحات هيئة الأوراق المالية والبورصات، باستثناء تصريحات الملكية التي نقدمها في مكان آخر.
| September 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 28, 2025 Sharps Technology, Inc. |
|
| September 2, 2025 |
As filed with the Securities and Exchange Commission on September 2, 2025 As filed with the Securities and Exchange Commission on September 2, 2025 Registration No. |
|
| September 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 2, 2025 Sharps Technology, Inc. |
|
| September 2, 2025 |
Up to $236,605,575 Common Stock Filed Pursuant to Rule 424(b)(5) Registration Nos. 333-274146 and 333-289980 Prospectus Supplement (To Prospectus dated September 5, 2023) Up to $236,605,575 Common Stock We have entered into a Controlled Equity OfferingSM Sales Agreement (the “sales agreement”) with Cantor Fitzgerald & Co. (“Cantor”), and Aegis Capital Corp. (“Aegis” and together with Cantor, the “Agents” and each, an “Agent”) re |
|
| September 2, 2025 |
EXHIBIT 107 Calculation of Filing Fee Table Form S-3 Sharps Technology, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1. Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule(1) Amount Registered Proposed Maximum Offering Price Per Security Proposed Maximum Aggregate Offering Price Fee Rate Amount of Registration |
|
| September 2, 2025 |
Exhibit 10.4 STRATEGIC ADVISOR AGREEMENT THIS STRATEGIC ADVISOR AGREEMENT (this “Agreement”) is made and entered into as of the Closing Date (as defined in the Securities Purchase Agreements, dated August 25, 2025) (the “Effective Date”) by and between Sharps Technology Inc., a Nevada corporation (the “Company”), and Sol Markets, a Cayman Islands exempt company (the “Strategic Advisor”). WHEREAS, |
|
| September 2, 2025 |
FORM OF STRATEGIC ADVISORY WARRANT SHARPS TECHNOLOGY, INC. Exhibit 4.6 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| September 2, 2025 |
Exhibit 10.5 CONSULTING AGREEMENT This CONSULTING AGREEMENT (this “Agreement”), effective as of the final closing of the Capital Raise (as defined below) (the “Effective Date”), is entered into by and between Sharps Technology Inc., a Nevada corporation (the “Client” or the “Company”) and Sol Edge Limited, a Cayman Islands exempt company or its designated affiliate (the “Consultant” and, with the |
|
| September 2, 2025 |
Exhibit 99.2 Privileged & Confidential Prepared at the Direction of Counsel Close Press Release Sharps Technology, Inc. Closes Over $400 Million Private Placement, Launching Solana Digital Asset Treasury Strategy Transaction could raise up to $1 billion in aggregate gross proceeds if all of the warrants are exercised, which would make Sharps Technology one of the largest Solana treasury companies |
|
| September 2, 2025 |
Exhibit 1.1 Execution Version SHARPS TECHNOLOGY, INC. Shares of Common Stock (par value $0.0001 per share) Controlled Equity OfferingSM Sales Agreement September 2, 2025 Cantor Fitzgerald & Co. 110 East 59th Street New York, New York 10022 Aegis Capital Corp. 1345 Avenue of the Americas, 27th Floor New York, New York 10105 Ladies and Gentlemen: Sharps Technology, Inc., a Nevada corporation (the “C |
|
| August 25, 2025 |
Exhibit 3.1 |
|
| August 25, 2025 |
Exhibit 4.3 WARRANT AGREEMENT THIS WARRANT AGREEMENT (this “Agreement”), dated as of [], 2025, is by and between Sharps Technology, Inc., a Nevada corporation (the “Company”), and VStock Transfer, LLC, as warrant agent (in such capacity, the “Warrant Agent,” and also referred to herein as the “Transfer Agent”). WHEREAS, the Company desires to sell to each Purchaser (as defined in the Securities Pu |
|
| August 25, 2025 |
SEPARATION AND RELEASE AGREEMENT Exhibit 10.6 SEPARATION AND RELEASE AGREEMENT This Separation and Release Agreement (this “Agreement”), by and between Sharps Technology Inc., a Nevada corporation (the “Company”) and Robert Hayes (“Employee”), is being offered to Employee on August 21, 2025 (the “Offer Date”), and may be accepted by Employee by signing the Agreement without change and returning it to the Company no later than 6:0 |
|
| August 25, 2025 |
Exhibit 10.2 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of August 25, 2025, between Sharps Technology, Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and conditions |
|
| August 25, 2025 |
Exhibit 10.4 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this “Agreement”), dated August 23, 2025 (the “Effective Date”), is entered into by and between Sharps Technology, Inc. (the “Company”) and Yuwen Zhang (the “Executive”). WHEREAS, the Company desires to employ the Executive and the Company and the Executive desire to enter into an agreement embodying the terms of such employment, subject |
|
| August 25, 2025 |
Exhibit 10.5 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this “Agreement”), dated August 23, 2025 (the “Effective Date”), is entered into by and between Sharps Technology, Inc. (the “Company”) and Paul Danner (the “Executive”). WHEREAS, the Company desires to employ the Executive and the Company and the Executive desire to enter into an agreement embodying the terms of such employment, subject |
|
| August 25, 2025 |
Exhibit 99.1 Privileged & Confidential Prepared at the Direction of Counsel Press Release Sharps Technology, Inc. Announces Over $400 Million Private Placement Seeking to Establish the Largest Solana Digital Asset Treasury Strategy Investors include leading financial institutions and digital asset market leaders such as ParaFi, Pantera, Monarq, FalconX, Phoenix Capital, Bastion Trading, RockawayX, |
|
| August 25, 2025 |
FORM OF PRE-FUNDED COMMON STOCK PURCHASE WARRANT SHARPS TECHNOLOGY, INC. Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| August 25, 2025 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of August 25, 2025, between Sharps Technology, Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms and conditions |
|
| August 25, 2025 |
Exhibit 10.3 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of August 25, 2025, between Sharps Technology, Inc., a Nevada corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). This Agreement is made pursuant to the Securities Purchase |
|
| August 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): August 22, 2025 Sharps Technology, Inc. |
|
| August 25, 2025 |
FIRST AMENDMENT TO SERIES A WARRANT Exhibit 4.5 FIRST AMENDMENT TO SERIES A WARRANT This First Amendment to Series A Warrant (this “Amendment”), dated as of August 25, 2025, is by and between Sharps Technology, Inc., a Nevada corporation (the “Company”), and the undersigned (the “Holder”). Except as otherwise defined herein, all capitalized terms shall have the meanings set forth in the Series A Registered Common Warrant to Purchase |
|
| August 25, 2025 |
Exhibit 4.4 WARRANT AGREEMENT THIS WARRANT AGREEMENT (this “Agreement”), dated as of [], 2025, is by and between Sharps Technology, Inc., a Nevada corporation (the “Company”), and VStock Transfer, LLC, as warrant agent (in such capacity, the “Warrant Agent,” and also referred to herein as the “Transfer Agent”). WHEREAS, the Company desires to sell to each Purchaser (as defined in the Securities Pu |
|
| August 25, 2025 |
Exhibit 99.2 |
|
| August 25, 2025 |
FORM OF PRE-FUNDED COMMON STOCK PURCHASE WARRANT SHARPS TECHNOLOGY, INC. Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| August 22, 2025 |
As filed with the Securities and Exchange Commission on August 22, 2025 As filed with the Securities and Exchange Commission on August 22, 2025 Registration No. |
|
| August 22, 2025 |
Exhibit 107 Calculation of Filing Fee Table FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 (Form Type) SHARPS TECHNOLOGY, INC. |
|
| August 22, 2025 |
SHARPS TECHNOLOGY, INC. COMPENSATION RECOVERY POLICY Effective April 15, 2025 Exhibit 99.1 SHARPS TECHNOLOGY, INC. COMPENSATION RECOVERY POLICY Effective April 15, 2025 In accordance with Section 10D of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), Exchange Act Rule 10D-1, the listing rule of the Nasdaq Capital Market (the “Exchange”) where the securities of Sharps Technology, Inc. (the “Company”) are listed, the Company’s Board of Directors (the “Bo |
|
| August 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-41355 Sharps Technology, Inc. (Exact name of registrant as specified in |
|
| August 13, 2025 |
Employment Agreement, dated August 13, 2025, between the Company and Paul K Danner Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (“Agreement”) is made and entered into on August 13, 2025 but shall be effective as of the 1st day of July 2025, by and between Sharps Technology, Inc., a Nevada Corporation (the “Company”) and Paul K. Danner (the “Executive”) (together the Company and the Executive are the “Parties”) and supersedes and replaces any pr |
|
| August 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 (Amendment No. 3 to) SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as Permitted by Rule 14a-6(e)(2)) ☒ D |
|
| August 5, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 (Amendment No. 2 to) SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as Permitted by Rule 14a-6(e)(2)) ☒ D |
|
| July 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 (Amendment No. 2 to) SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as Permitted by Rule 14a-6(e)(2)) ☒ D |
|
| July 18, 2025 |
Exhibit 10.1 Sharps Technology Corp Series B Preferred Stock SUBSCRIPTION AND INVESTMENT REPRESENTATION AGREEMENT THIS AGREEMENT, dated as of July 15, 2025, is by and between Sharps Technology Corp, a Nevada corporation (the “Company”), and the undersigned subscriber (the “Subscriber”). In consideration of the mutual promises contained herein, and other good, valuable and adequate consideration, t |
|
| July 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 (Amendment No. 1 to) SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as Permitted by Rule 14a-6(e)(2)) ☐ D |
|
| July 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 15, 2025 Sharps Technology, Inc. |
|
| July 18, 2025 |
Certificate of Designation of Series D Preferred Stock, dated July 16, 2025 Exhibit 3.1 |
|
| July 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as Permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| July 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 30, 2025 Sharps Technology, Inc. |
|
| June 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 4, 2025 Sharps Technology, Inc. |
|
| June 4, 2025 |
Exhibit 99.1 Sharps Technology Begins Shipments Across Three Customer Orders Under Previously Announced Purchase Agreements Shipments include initial deliveries of SecureGard™ and SoloGard™ smart safety syringes from its Hungary-based manufacturing facility Deliveries mark the Company’s transition to a commercial-stage, revenue-generating company NEW YORK, June 4, 2025 (GLOBE NEWSWIRE) – Sharps Te |
|
| May 22, 2025 |
Sharps Technology Regains Compliance with Nasdaq Minimum Bid Price Listing Rule Exhibit 99.1 Sharps Technology Regains Compliance with Nasdaq Minimum Bid Price Listing Rule NEW YORK, May 22, 2025 (GLOBE NEWSWIRE) – Sharps Technology, Inc. (Nasdaq: “STSS” and “STSSW”) (“Sharps”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class smart-safety syringe products to the healthcare industry, announces that it has received a notice fro |
|
| May 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 22, 2025 Sharps Technology, Inc. |
|
| May 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-41355 Sharps Technology, Inc. (Exact name of registrant as specified i |
|
| May 15, 2025 |
Exhibit 14.1 |
|
| May 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 7, 2025 Sharps Technology, Inc. |
|
| May 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 6, 2025 Sharps Technology, Inc. |
|
| May 6, 2025 |
Exhibit 99.1 Sharps Technology Receives ~$100K Initial Purchase Order from Hungarian Vaccine Provider for SecureGard™ Syringes Sharps also received an initial qualification purchase order for DisGard™ single-use Sharps Recovery System Company transitions to revenue producing with second purchase order, bringing total recent orders to approximately $500,000 for the quarter NEW YORK, May 6, 2025 (GL |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 30, 2025 Sharps Technology, Inc. |
|
| April 30, 2025 |
Exhibit 99.1 Sharps Technology Secures $400K Initial Purchase Order from U.S. Leader in IV Flushing Solutions as Part of $50 Million SoloGard Supply Agreement Milestone order marks first commercial revenue for Sharps Technology under multi-year, 500-million syringe agreement Investments in best-in-class manufacturing equipment position Sharps to offer differentiated high-volume syringe production |
|
| April 30, 2025 |
Certificate of Amendment to Certificate of Incorporation filed April 25, 2025 Exhibit 3.1 |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 25, 2025 Sharps Technology, Inc. |
|
| April 25, 2025 |
Sharps Technology Announces Reverse Stock Split Exhibit 99.1 Sharps Technology Announces Reverse Stock Split NEW YORK, April 24, 2025 (GLOBE NEWSWIRE) - Sharps Technology, Inc. (NASDAQ: “STSS” and “STSSW”) (“Sharps”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class smart-safety syringe products to the healthcare industry, today announced that it will effect a 1-for-300 reverse stock split (the |
|
| April 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 24, 2025 Sharps Technology, Inc. |
|
| April 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 15, 2025 Sharps Technology, Inc. |
|
| April 15, 2025 |
Exhibit 99.1 SHARPS TECHNOLOGY, INC. COMPENSATION RECOVERY POLICY Effective April 15, 2025 In accordance with Section 10D of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), Exchange Act Rule 10D-1, the listing rule of the Nasdaq Capital Market (the “Exchange”) where the securities of Sharps Technology, Inc. (the “Company”) are listed, the Company’s Board of Directors (the “Bo |
|
| April 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-41355 Sharps Technology, Inc. (Exact name of registrant as specified in i |
|
| April 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 14, 2025 Sharps Technology, Inc. |
|
| April 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 3, 2025 Sharps Technology, Inc. |
|
| April 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): April 3, 2025 Sharps Technology, Inc. |
|
| April 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 28, 2025 Sharps Technology, Inc. |
|
| March 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 28, 2025 Sharps Technology, Inc. |
|
| March 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-41355 Sharps Technology, Inc. (Exact name of registrant as specified in its |
|
| March 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as Permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| March 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 20, 2025 Sharps Technology, Inc. |
|
| March 20, 2025 |
Exhibit 99.1 Sharps Technology, Inc. Reminds Shareholders to Vote Before Important Shareholder Meeting on March 28, 2025 Voting ‘FOR’ the Proposed Stock Split is Crucial to Keep STSS Listed on Nasdaq and Prevent Delisting to the OTC Markets NEW YORK, March 20, 2025 (GLOBE NEWSWIRE) — Sharps Technology, Inc. (Nasdaq: STSS) (the “Company” or “Sharps”), an innovative medical device and pharmaceutical |
|
| March 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 12, 2025 Sharps Technology, Inc. |
|
| February 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as Permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| January 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as Permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| January 31, 2025 |
EX-99.1 2 ex991to13g10022stss013125.htm Exhibit 99.1 Joint Filing Agreement The undersigned hereby agree that the Statement on Schedule 13G dated January 31, 2025 with respect to the shares of Common Stock of Sharps Technology Inc. and any further amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with th |
|
| January 31, 2025 |
Sharps Technology, Inc. 105 Maxess Road, Ste. 124 Melville, New York 11747 Sharps Technology, Inc. 105 Maxess Road, Ste. 124 Melville, New York 11747 January 31, 2025 VIA EMAIL U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, DC 20549 Attention: Robert Augustine Re: Sharps Technology, Inc. Amendment No. 3 Registration Statement on Form S-1 (File No. 333-284237) Amendment No. 1 to Form AW, filed on January 29, 2025 Ladie |
|
| January 30, 2025 |
Underwriting Agreement between the Company and Aegis Capital Corp., dated January 28, 2025 Exhibit 10.1 |
|
| January 30, 2025 |
Sharps Technology, Inc. Announces Closing of Upsized $20.0 Million Underwritten Public Offering Exhibit 99.2 Sharps Technology, Inc. Announces Closing of Upsized $20.0 Million Underwritten Public Offering NEW YORK, NY, JANUARY 29, 2025 (GLOBE NEWSWIRE) — Sharps Technology, Inc. (NASDAQ: STSS) (the “Company”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, today announced the closing of its previously announced firm commitm |
|
| January 30, 2025 |
Exhibit 4.1 REGISTERED PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK SHARPS TECHNOLOGY, INC. Warrant Shares: [●] Initial Exercise Date: January 29, 2025 Issuance Date: January 29, 2025 THIS PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK (the “Warrant”) certifies that, for value received, [●] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the con |
|
| January 30, 2025 |
Exhibit 4.3 SERIES B REGISTERED COMMON WARRANT TO PURCHASE COMMON STOCK SHARPS TECHNOLOGY, INC. Warrant Shares: [●] Issuance Date: January 29, 2025 THIS WARRANT TO PURCHASE COMMON STOCK (the “Warrant”) certifies that, for value received, [●] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on |
|
| January 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 28, 2025 Sharps Technology, Inc. |
|
| January 30, 2025 |
Exhibit 4.2 SERIES A REGISTERED COMMON WARRANT TO PURCHASE COMMON STOCK SHARPS TECHNOLOGY, INC. Warrant Shares: [●] Issuance Date: January 29, 2025 THIS WARRANT TO PURCHASE COMMON STOCK (the “Warrant”) certifies that, for value received, [●] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on |
|
| January 30, 2025 |
Sharps Technology, Inc. Announces Pricing of Upsized $20.0 Million Underwritten Public Offering Exhibit 99.1 Sharps Technology, Inc. Announces Pricing of Upsized $20.0 Million Underwritten Public Offering NEW YORK, NY, JANUARY 28, 2025 (GLOBE NEWSWIRE) — Sharps Technology, Inc. (NASDAQ: STSS) (the “Company”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, today announced the pricing of a firm commitment underwritten public |
|
| January 29, 2025 |
Exhibit 107 Calculation of Filing Fee Tables S-1 (Form Type) Sharps Technology, Inc. |
|
| January 29, 2025 |
Registration No. 333-284237 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 POST EFFECTIVE AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Sharps Technology, Inc. (Exact name of registrant as specified in its charter) Nevada 3841 82-3751728 (State or other jurisdiction of (Primary Standard Industrial (I.R.S. Employer incorporation or orga |
|
| January 29, 2025 |
Filed Pursuant to Rule 424(b)(4) Registration No. 333-284237 3,452,214 Units, with each Unit consisting of: One Share of Common Stock One Series A Warrant to Purchase One Share of Common Stock One Series B Warrant to Purchase One Share of Common Stock 10,833,500 Pre-Funded Units, with each Pre-Funded Unit consisting of: One Pre-Funded Warrant to Purchase One Share of Common Stock One Series A Warr |
|
| January 29, 2025 |
Sharps Technology, Inc. 105 Maxess Road, Ste. 124 Melville, New York 11747 January 29, 2025 Sharps Technology, Inc. 105 Maxess Road, Ste. 124 Melville, New York 11747 January 29, 2025 VIA EMAIL U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, DC 20549 Attention: Robert Augustine Re: Sharps Technology, Inc. Amendment No. 3 Registration Statement on Form S-1 (File No. 333-284237) Ladies and Gentlemen: Pursuant to Rule 477 under the Securi |
|
| January 28, 2025 |
Registration No. 333-284237 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO. 4 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Sharps Technology, Inc. (Exact name of registrant as specified in its charter) Nevada 3841 82-3751728 (State or other jurisdiction of (Primary Standard Industrial (I.R.S. Employer incorporation or organization) Class |
|
| January 28, 2025 |
Exhibit 107 Calculation of Filing Fee Tables S-1 (Form Type) Sharps Technology, Inc. |
|
| January 27, 2025 |
Exhibit 3.5 SERIES B REGISTERED COMMON WARRANT TO PURCHASE COMMON STOCK SHARPS TECHNOLOGY, INC. Warrant Shares: [●] Issuance Date: [●], 2025 THIS WARRANT TO PURCHASE COMMON STOCK (the “Warrant”) certifies that, for value received, [●] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or afte |
|
| January 27, 2025 |
Exhibit 3.4 SERIES A REGISTERED COMMON WARRANT TO PURCHASE COMMON STOCK SHARPS TECHNOLOGY, INC. Warrant Shares: [●] Issuance Date: [●], 2025 THIS WARRANT TO PURCHASE COMMON STOCK (the “Warrant”) certifies that, for value received, [●] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or afte |
|
| January 27, 2025 |
Exhibit 107 Calculation of Filing Fee Tables S-1 (Form Type) Sharps Technology, Inc. |
|
| January 27, 2025 |
Exhibit 3.5 SERIES B REGISTERED COMMON WARRANT TO PURCHASE COMMON STOCK SHARPS TECHNOLOGY, INC. Warrant Shares: [●] Issuance Date: [●], 2025 THIS WARRANT TO PURCHASE COMMON STOCK (the “Warrant”) certifies that, for value received, [●] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or afte |
|
| January 27, 2025 |
Exhibit 3.4 SERIES A REGISTERED COMMON WARRANT TO PURCHASE COMMON STOCK SHARPS TECHNOLOGY, INC. Warrant Shares: [●] Issuance Date: [●], 2025 THIS WARRANT TO PURCHASE COMMON STOCK (the “Warrant”) certifies that, for value received, [●] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or afte |
|
| January 27, 2025 |
Registration No. 333-284237 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO. 3 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Sharps Technology, Inc. (Exact name of registrant as specified in its charter) Nevada 3841 82-3751728 (State or other jurisdiction of (Primary Standard Industrial (I.R.S. Employer incorporation or organization) Class |
|
| January 27, 2025 |
Registration No. 333-284237 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO. 2 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Sharps Technology, Inc. (Exact name of registrant as specified in its charter) Nevada 3841 82-3751728 (State or other jurisdiction of (Primary Standard Industrial (I.R.S. Employer incorporation or organization) Class |
|
| January 23, 2025 |
January 23, 2025 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| January 23, 2025 |
Sharps Technology, Inc. 105 Maxess Road Melville, NY 11747 Sharps Technology, Inc. 105 Maxess Road Melville, NY 11747 January 23, 2025 Securities and Exchange Commission Division of Corporation Finance 100 F Street N.E. Washington, D.C. 20549 Re: Sharps Technology, Inc. Registration Statement on Form S-1/A Filed January 22, 2025 File No. 333-284237 Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Sharps |
|
| January 22, 2025 |
Amended and Restated Bylaws of Sharps Technology, Inc., as adopted on January 21, 2025. Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF SHARPS TECHNOLOGY, INC. (a Nevada corporation) TABLE OF CONTENTS ARTICLE I – OFFICES 1.1 Registered Agent and Office 3 1.2 Principal Office 3 1.3 Other Offices 3 1.4 Books and Records 3 ARTICLE II - STOCKHOLDERS 2.1 Place of meeting 3 2.2 Participation by Remote Communication 3 2.3 Annual Meeting 4 2.4 Special Meetings 4 2.5 Fixing the Record Date 4 2.6 N |
|
| January 22, 2025 |
Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF SHARPS TECHNOLOGY, INC. (a Nevada corporation) TABLE OF CONTENTS ARTICLE I – OFFICES 1.1 Registered Agent and Office 3 1.2 Principal Office 3 1.3 Other Offices 3 1.4 Books and Records 3 ARTICLE II - STOCKHOLDERS 2.1 Place of meeting 3 2.2 Participation by Remote Communication 3 2.3 Annual Meeting 4 2.4 Special Meetings 4 2.5 Fixing the Record Date 4 2.6 N |
|
| January 22, 2025 |
Form of Underwriting Agreement, dated [___], 2025, between the Company and Aegis Capital Corp.* Exhibit 1.1 Underwriting Agreement [●], 2025 Aegis Capital Corp. 1345 Avenue of the Americas, 27th Floor New York, NY 10105 Ladies and Gentlemen: Sharps Technology, Inc., a Nevada corporation (the “Company”), agrees, subject to the terms and conditions in this agreement (this “Agreement”), to issue and sell to Aegis Capital Corp. (the “Underwriter”) an aggregate of [●] of the Company’s units (each |
|
| January 22, 2025 |
Exhibit 24.1 POWER OF ATTORNEY KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Robert M. Hayes, as his true and lawful attorney-in-fact and agent with full power of substitution, for him in any and all capacities, to sign any and all amendments to this registration statement (including post-effective amendments or any abbreviated r |
|
| January 22, 2025 |
Exhibit 107 Calculation of Filing Fee Tables S-1 (Form Type) Sharps Technology, Inc. |
|
| January 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 21, 2025 Sharps Technology, Inc. |
|
| January 22, 2025 |
Exhibit 10.36 SHARPS TECHNOLOGY, INC. 2024 EQUITY INCENTIVE PLAN 1. Purpose; Eligibility. 1.1 General Purpose. The name of this plan is the Sharps Technology, Inc., 2024 Equity Incentive Plan (the “Plan”). The purposes of the Plan are to (a) enable Sharps Technology, Inc., a Nevada corporation (the “Company”), and any Affiliate to attract and retain the types of Directors, Employees and Consultant |
|
| January 22, 2025 |
Registration No. 333-284237 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Sharps Technology, Inc. (Exact name of registrant as specified in its charter) Nevada 3841 82-3751728 (State or other jurisdiction of (Primary Standard Industrial (I.R.S. Employer incorporation or organization) Class |
|
| January 10, 2025 |
Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Sharps Technology, Inc. (Exact name of registrant as specified in its charter) Nevada 3841 82-3751728 (State or other jurisdiction of (Primary Standard Industrial (I.R.S. Employer incorporation or organization) Classification Code Number) Id |
|
| January 10, 2025 |
Form of Underwriting Agreement, dated [___], 2025, between the Company and Aegis Capital Corp. Exhibit 1.1 Underwriting Agreement [●], 2025 Aegis Capital Corp. 1345 Avenue of the Americas, 27th Floor New York, NY 10105 Ladies and Gentlemen: Sharps Technology, Inc., a Nevada corporation (the “Company”), agrees, subject to the terms and conditions in this agreement (this “Agreement”), to issue and sell to Aegis Capital Corp. (the “Underwriter”) an aggregate of [●] of the Company’s units (each |
|
| January 10, 2025 |
Exhibit 10.36 SHARPS TECHNOLOGY, INC. 2024 EQUITY INCENTIVE PLAN 1. Purpose; Eligibility. 1.1 General Purpose. The name of this plan is the Sharps Technology, Inc., 2024 Equity Incentive Plan (the “Plan”). The purposes of the Plan are to (a) enable Sharps Technology, Inc., a Nevada corporation (the “Company”), and any Affiliate to attract and retain the types of Directors, Employees and Consultant |
|
| January 10, 2025 |
Exhibit 107 Calculation of Filing Fee Tables S-1 (Form Type) Sharps Technology, Inc. |
|
| December 31, 2024 |
Sharps Technology, Inc. 105 Maxess Road Melville, NY 11747 Sharps Technology, Inc. 105 Maxess Road Melville, NY 11747 December 31, 2024 Securities and Exchange Commission Division of Corporation Finance 100 F Street N.E. Washington, D.C. 20549 Re: Sharps Technology, Inc. Registration Statement on Form S-3 Filed December 23, 2024 File No. 333-284028 Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Sharps |
|
| December 23, 2024 |
As filed with the Securities and Exchange Commission on December 23, 2024, As filed with the Securities and Exchange Commission on December 23, 2024, Registration Statement No. |
|
| December 23, 2024 |
Submission of Matters to a Vote of Security Holders, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 19, 2024 Sharps Technology, Inc. |
|
| December 23, 2024 |
Calculation of Filing Fee Table Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Sharps Technology, Inc. |
|
| December 9, 2024 |
Sharps Technology, Inc. ® 1,945,591 Shares of Common Stock Filed Pursuant to Rule 253(g)(3) File No. 024-12438 OFFERING CIRCULAR Sharps Technology, Inc. ® 1,945,591 Shares of Common Stock By this offering circular (the “Offering Circular”), Sharps Technology, Inc., a Nevada corporation, is offering on a “best-efforts” basis a maximum of 1,945,591 shares of its common stock, par value $0.0001 per share (the “Offered Shares”), at a fixed price of $1.95 per |
|
| December 6, 2024 |
Form of Subscription Agreement dated December 5, 2024. Exhibit 4.1 NOTICE TO INVESTORS THIS INVESTMENT INVOLVES A HIGH DEGREE OF RISK, SUITABLE ONLY FOR PERSONS WHO CAN BEAR THE ECONOMIC RISK FOR AN INDEFINITE PERIOD OF TIME AND WHO CAN AFFORD TO LOSE THEIR ENTIRE INVESTMENT. INVESTORS SHOULD FURTHER UNDERSTAND THAT THIS INVESTMENT IS ILLIQUID AND IS EXPECTED TO CONTINUE TO BE ILLIQUID FOR AN INDEFINITE PERIOD OF TIME. THE SECURITIES OFFERED HEREBY HA |
|
| December 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 5, 2024 Sharps Technology, Inc. |
|
| December 5, 2024 |
Exhibit 99.1 Sharps Technology’s CEO Issues Shareholder Letter Highlighting Hungary Manufacturing Facility Expansion Plans to Increase SecureGard and SoloGard Product Supply and Revenue ● Shareholder letter includes details about the $50+ million sales agreement with a US-based pharma company, plans for Hungary SoloGard manufacturing expansion, and expected delivery schedule ● Initial production a |
|
| December 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 5, 2024 Sharps Technology, Inc. |
|
| December 5, 2024 |
Exhibit 99.1 Sharps Technology Signs Sales Agreements to Support Major European Healthcare Network and Sells Out Its Inventory for SecureGard ● Signed multiple agreements to sell its SecureGard syringe inventory, with initial shipments and revenue commencing in early December ● Agreements also include new forecasted orders and commitments for all current SecureGard capacity, to begin in Q2 2025 ● |
|
| December 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 5, 2024 Sharps Technology, Inc. |
|
| December 4, 2024 |
December 4, 2024 VIA EDGAR United States Securities and Exchange Commission 100 F. |
|
| November 27, 2024 |
Sharps Technology, Inc. November 27, 2024 Via EDGAR Division of Corporation Finance Office of Industrial Applications and Services U.S. Securities and Exchange Commission 100 F Street, NE Washington, D.C., 20549 Attention: Juan Grana Re: Sharps Technology, Inc. Registration Statement on Form S-3 Initially Filed on October 23, 2024 File No. 333-282796 Mr. Grana: In accordance with Rule 461 of the G |
|
| November 26, 2024 |
PRELIMINARY OFFERING CIRCULAR DATED NOVEMBER 26, 2024 Post-Qualification Offering Circular Pursuant to Rule 251(d)(3) and 253(b) Amendment No. |
|
| November 26, 2024 |
November 26, 2024 VIA EDGAR United States Securities and Exchange Commission 100 F. |
|
| November 26, 2024 |
Exhibit 11.2 |
|
| November 26, 2024 |
Exhibit 11.1 |
|
| November 26, 2024 |
Exhibit 12.1 November 26, 2024 Sharps Technology, Inc. 105 Maxess Road, Suite 124 Melville, NY 11747 Re: Offering Statement on Form 1-A/A Ladies and Gentlemen: We have acted as counsel to Sharps Technology, Inc. a Nevada corporation (the “Company”), in connection with the preparation and filing of an offering statement on Form 1-A (the “Offering Statement”). The Offering Statement covers the conte |
|
| November 22, 2024 |
As filed with the Securities and Exchange Commission on November 22, 2024, As filed with the Securities and Exchange Commission on November 22, 2024, Registration Statement No. |
|
| November 22, 2024 |
Calculation of Filing Fee Table Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Sharps Technology, Inc. |
|
| November 18, 2024 |
Exhibit 12.1 November 18, 2024 Sharps Technology, Inc. 105 Maxess Road, Suite 124 Melville, NY 11747 Re: Offering Statement on Form 1-A Ladies and Gentlemen: We have acted as counsel to Sharps Technology, Inc. a Nevada corporation (the “Company”), in connection with the preparation and filing of an offering statement on Form 1-A (the “Offering Statement”). The Offering Statement covers the contemp |
|
| November 18, 2024 |
Exhibit 11.1 |
|
| November 18, 2024 |
Form 1-A/A (File No. 024-12438) PRELIMINARY OFFERING CIRCULAR DATED NOVEMBER 18, 2024 AN OFFERING STATEMENT PURSUANT TO REGULATION A RELATING TO THESE SECURITIES HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. |
|
| November 18, 2024 |
Exhibit 11.2 |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-41355 Sharps Technolog |
|
| November 13, 2024 |
STSS / Sharps Technology, Inc. / Walleye Capital LLC Passive Investment SC 13G/A 1 walleye-stss093024a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Sharps Technology, Inc. (Name of Issuer) Common Stock Purchase Warrants (Title of Class of Securities) 82003F119 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appro |
|
| November 7, 2024 |
Amended and Restated Bylaws of Sharps Technology, Inc., as adopted on November 4, 2024. Exhibit 3.1 BYLAWS OF SHARPS TECHNOLOGY, INC. (a Nevada corporation) TABLE OF CONTENTS ARTICLE I – OFFICES 1.1 Registered Agent and Office 3 1.2 Principal Office 3 1.3 Other Offices 3 1.4 Books and Records 3 ARTICLE II - STOCKHOLDERS 2.1 Place of meeting 3 2.2 Participation by Remote Communication 3 2.3 Annual Meeting 4 2.4 Special Meetings 4 2.5 Fixing the Record Date 4 2.6 Notice of Stockholders |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 4, 2024 Sharps Technology, Inc. |
|
| November 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as Permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| October 23, 2024 |
As filed with the Securities and Exchange Commission on October 23, 2024, As filed with the Securities and Exchange Commission on October 23, 2024, Registration Statement No. |
|
| October 23, 2024 |
Calculation of Filing Fee Table EX-FILING FEES 5 ex107.htm CALCULATION OF FILING FEE TABLE Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Sharps Technology, Inc. (Exact name of Registrant as Specified in its Charter) Proposed Maximum Maximum Security Fee Offering Aggregate Amount of Security Class Calculation Amount Price Per Offering Registration Type Title Rule Registered(1) Share(2) Price Fee Rate Fee(2) Fee |
|
| October 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 14, 2024 Sharps Technology, Inc. |
|
| October 15, 2024 |
Exhibit 99.1 SHARPS TECHNOLOGY, INC. ANNOUNCES STOCKHOLDERS’ APPROVAL OF REVERSE STOCK SPLIT RATIO AND EFFECTIVE DATE October 14, 2024 NEW YORK, October 14, 2024 / Sharps Technology, Inc. (NASDAQ: “STSS” and “STSSW”) (“Sharps”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, today announced that it will effect a one-for-22 rever |
|
| October 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): October 7, 2024 Sharps Technology, Inc. |
|
| October 9, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Sharps Technology Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 82003F101 (CUSIP Number) September 30, 2024 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which |
|
| September 30, 2024 |
Exhibit 99.1 Sharps Technology, Inc. Reminds Shareholders to Vote Before Important Shareholder Meeting on October 7, 2024 NEW YORK, Sept. 30, 2024 (GLOBE NEWSWIRE) — Sharps Technology, Inc. (NASDAQ: STSS) (the “Company”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, is reminding shareholders to vote their proxy in favor of the |
|
| September 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as Permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| September 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 30, 2024 Sharps Technology, Inc. |
|
| September 23, 2024 |
Exhibit 10.3 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of September 20, 2024, between Sharps Technology, Inc., a Nevada corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”). This Agreement is made pursuant to the Securities Purch |
|
| September 23, 2024 |
Form of Securities Purchase Agreement Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of September 20, 2024, between Sharps Technology, Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (including their respective successors and assigns, each a “Purchaser” and collectively, the “Purchasers”). WHEREAS, subject to the terms |
|
| September 23, 2024 |
Exhibit 10.2 [FORM OF SENIOR SECURED NOTE] THIS SECURITY HAS NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURI |
|
| September 23, 2024 |
Form of the Placement Agent Agreement Exhibit 10.4 September [●], 2024 PERSONAL AND CONFIDENTIAL Mr. Robert M. Hayes, Chief Executive Officer Sharps Technology, Inc. 105 Maxess Road Melville, New York 11747 Re: STSS | Note Offering | Placement Agent Agreement Dear Mr. Hayes: The purpose of this placement agent agreement is to outline our agreement pursuant to which Aegis Capital Corp. (“Aegis”) will act as the placement agent on a “be |
|
| September 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 20, 2024 Sharps Technology, Inc. |
|
| September 23, 2024 |
Sharps Technology, Inc. Announces $3.5 Million Bridge Financing Exhibit 99.1 Sharps Technology, Inc. Announces $3.5 Million Bridge Financing NEW YORK, NY, September 23, 2024 (GLOBAL NEWSWIRE) — Sharps Technology, Inc. (NASDAQ: STSS) (the “Company”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, today announced that it has entered into definitive agreements with institutional investors for a |
|
| September 23, 2024 |
Exhibit 10.5 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| September 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 12, 2024 Sharps Technology, Inc. |
|
| September 12, 2024 |
Exhibit 99.1 Sharps Technology Announces Continued Listing on Nasdaq Pending Results of an Upcoming Special Shareholders’ Meeting New York, NY — Sharps Technology, Inc., (NASDAQ: STSS and STSSW) (“Sharps Technology” or the “Company”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, announced today that the Company has secured app |
|
| September 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as Permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| August 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as Permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-41355 Sharps Technology, In |
|
| July 30, 2024 |
Certificate of Amendment to the Articles of Incorporation Exhibit 3.1 |
|
| July 30, 2024 |
Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 23, 2024 Sharps Technology, Inc. |
|
| July 25, 2024 |
Exhibit 10.1 Stericare Solutions and Sharps Technology, Inc. Supply Agreement This Supply Agreement (“Agreement”) is entered into on July 24th, 2024, by and between Sharps Technology, Inc., a Nevada corporation (“Seller”), and Stericare Solutions, LLC a Texas limited liability company (“Buyer”), having an address of 4409 Haltom Road, Haltom City, TX 76117. Seller manufactures and sells syringe for |
|
| July 25, 2024 |
Exhibit 99.1 Sharps Technology Enters Into a Five-Year Sales Agreement with Strategic U.S. Medical Products Company Creating +$5O Million in New Revenue for EU Facility Definitive agreement sells out the 10mL SoloGard production capacity at Sharps’ manufacturing site in the EU and drives expansion to support the project’s growth in the future Sharps’ portfolio of products provides attractive optio |
|
| July 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 24, 2024 Sharps Technology, Inc. |
|
| July 18, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 15, 2024 Sharps Technology, Inc. |
|
| July 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 9, 2024 Sharps Technology, Inc. |
|
| July 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 9, 2024 Sharps Technology, Inc. |
|
| July 9, 2024 |
Exhibit 99.1 Sharps Technology CEO Urges Shareholders to Vote in Support of the Three Proposals by the July 12 Voting Deadline Robert Hayes issues a letter to shareholders asking their voting approval on three proposals vital to the Company’s continued growth. Voting deadline is Friday, July 12, at 11:59 p.m. Eastern Time. NEW YORK, JULY 9, 2024 – Sharps Technology, Inc., (NASDAQ: “STSS” and “STSS |
|
| July 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as Permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| July 3, 2024 |
Exhibit 99.1 Sharps Technology Urges Shareholders to Approve the Proposals in connection with the Special Meeting on July 15, 2024 All shareholders of record as of May 17, 2024 are eligible to vote Final votes must be cast by 11:59 p.m., Eastern Time on July 12, 2024 NEW YORK, July 3, 2024 – Sharps Technology, Inc. (NASDAQ: “STSS” and “STSSW’) (the “Company”), an innovative medical device and phar |
|
| July 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): July 3, 2024 Sharps Technology, Inc. |
|
| July 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as Permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| June 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as Permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| June 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Amendment No. 1 Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as Permitted by Rule 14a-6(e)(2)) ☐ Defini |
|
| June 25, 2024 |
Sharps Technology, Inc. 105 Maxess Road, Ste. #124 Melville, NY 11747 Sharps Technology, Inc. 105 Maxess Road, Ste. #124 Melville, NY 11747 June 25, 2024 Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 Division of Corporation Finance Attention: Nicholas O’Leary and Abby Adams Re: Sharps Technology, Inc. Preliminary Proxy Statement on Schedule 14A Filed June 5, 2024 File No. 001-41355 Dear Mr. O’Leary/ Ms. Adams: As discussed on certain ca |
|
| June 24, 2024 |
June 24, 2024 Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 Division of Corporation Finance Attention: Nicholas O’Leary and Abby Adams Re: Sharps Technology, Inc. Preliminary Proxy Statement on Schedule 14A Filed June 5, 2024 File No. 001-41355 Dear Mr. O’Leary/ Ms. Adams: As discussed on certain calls, Sharps Technology, Inc. (the “Company”) is hereby responding to t |
|
| June 21, 2024 |
June 21, 2024 Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 Division of Corporation Finance Attention: Nicholas O’Leary and Abby Adams Re: Sharps Technology, Inc. Preliminary Proxy Statement on Schedule 14A Filed June 5, 2024 File No. 001-41355 Dear Mr. O’Leary/ Ms. Adams: As discussed on certain calls, Sharps Technology, Inc. (the “Company”) is hereby responding to t |
|
| June 21, 2024 |
June 21, 2024 Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 Division of Corporation Finance Attention: Nicholas O’Leary and Abby Adams Re: Sharps Technology, Inc. Preliminary Proxy Statement on Schedule 14A Filed June 5, 2024 File No. 001-41355 Dear Mr. O’Leary: As discussed on certain calls, Sharps Technology, Inc. (the “Company”) is hereby responding to the comments |
|
| June 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 13, 2024 Sharps Technology, Inc. |
|
| June 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 13, 2024 Sharps Technology, Inc. |
|
| June 13, 2024 |
Exhibit 99.1 Sharps Technology Receives $30 Million Purchase Order for Prefillable Copolymer Syringes to be Manufactured at SC Facility Signed PO secures first 12 months of syringe product orders against Sharps and Nephron’s five-year, $200 million Syringe Sales Agreement. Current Asset Purchase Agreement closing timeline is on track for expected prefillable syringe product shipments to begin by Q |
|
| June 5, 2024 |
Sharps Technology Secures SC Asset Purchase Exclusivity with $1 Million Escrow Deposit Exhibit 99.1 Sharps Technology Secures SC Asset Purchase Exclusivity with $1 Million Escrow Deposit InjectEZ acquisition establishing Sharps position in the prefillable syringe (PFS) industry in the U.S. has progressed with the payment of $1 million into third-party escrow account. Closing on the Asset Purchase and the Syringe Sales Agreement, for product orders totaling over $200 million for the |
|
| June 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 5, 2024 Sharps Technology, Inc. |
|
| June 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as Permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| June 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 4, 2024 Sharps Technology, Inc. |
|
| June 4, 2024 |
Sharps Technology, Inc. ® 47,000,000 Shares of Common Stock Filed Pursuant to Rule 253(g)(3) File No. 024-12438 OFFERING CIRCULAR Sharps Technology, Inc. ® 47,000,000 Shares of Common Stock By this offering circular (the “Offering Circular”), Sharps Technology, Inc., a Nevada corporation, is offering on a “best-efforts” basis a maximum of 47,000,000 shares of its common stock, par value $0.0001 per share (the “Offered Shares”), at a fixed price of $0.38 pe |
|
| June 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K/A CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 30, 2024 Sharps Technology, Inc. |
|
| June 3, 2024 |
Form of New Warrant (incorporated by reference to current report on Form 8-K filed on June 3, 2024) Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| June 3, 2024 |
Form of Warrant Inducement Agreement by and between Sharps Technology, Inc. and Holder(s) Exhibit 10.1 SHARPS TECHNOLOGY, INC. May 30, 2024 Holder of Common Stock Purchase Warrant Re: Inducement Offer to Exercise Common Stock Purchase Warrants Dear Holder: Sharps Technology, Inc. (the “Company”) is pleased to offer to you (the “Holder”) the opportunity to exercise up to [ ] of the Warrants to Purchase Common Stock (including those originally issued on February 3, 2023 and those origina |
|
| May 31, 2024 |
Exhibit 99.1 Sharps Technology’s SC Asset Purchase and $200 Million Syringe Sales Agreement Paves the Way to Begin Producing Prefillable Specialty Copolymer Syringes in the U.S. Sharps CEO issues letter to shareholders with details about the InjectEZ acquisition, establishing Sharps position in the prefillable syringe (PFS) industry in the U.S. Signed Syringe Sales Agreement will secure product or |
|
| May 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 31, 2024 Sharps Technology, Inc. |
|
| May 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 30, 2024 Sharps Technology, Inc. |
|
| May 30, 2024 |
Form of Warrant Inducement Agreement by and between Sharps Technology, Inc. and Holder(s) Exhibit 10.1 SHARPS TECHNOLOGY, INC. May 30, 2024 Holder of Common Stock Purchase Warrant Re: Inducement Offer to Exercise Common Stock Purchase Warrants Dear Holder: Sharps Technology, Inc. (the “Company”) is pleased to offer to you (the “Holder”) the opportunity to exercise up to [ ] of the Warrants to Purchase Common Stock (including those originally issued on February 3, 2023 and those origina |
|
| May 30, 2024 |
Independent Registered Public Accounting Firm’s Consent Exhibit 11.2 Independent Registered Public Accounting Firm’s Consent We consent to the inclusion in this Amendment No. 2 to Form 1-A of Sharps Technology, Inc. (the “Offering Statement”) filed under the Securities Act of 1933, of our report dated March 28, 2024, with respect to our audit of the consolidated financial statements of Sharps Technology Inc. as of December 31, 2023, and for the year th |
|
| May 30, 2024 |
Exhibit 99.1 |
|
| May 30, 2024 |
Exhibit 4.1 NOTICE TO INVESTORS THIS INVESTMENT INVOLVES A HIGH DEGREE OF RISK, SUITABLE ONLY FOR PERSONS WHO CAN BEAR THE ECONOMIC RISK FOR AN INDEFINITE PERIOD OF TIME AND WHO CAN AFFORD TO LOSE THEIR ENTIRE INVESTMENT. INVESTORS SHOULD FURTHER UNDERSTAND THAT THIS INVESTMENT IS ILLIQUID AND IS EXPECTED TO CONTINUE TO BE ILLIQUID FOR AN INDEFINITE PERIOD OF TIME. THE SECURITIES OFFERED HEREBY HA |
|
| May 30, 2024 |
Exhibit 12.1 May 21, 2024 Sharps Technology, Inc. 105 Maxess Road, Suite 124 Melville, NY 11747 Re: Offering Statement on Form 1-A Ladies and Gentlemen: We have acted as counsel to Sharps Technology, Inc. a Nevada corporation (the “Company”), in connection with the preparation and filing of an offering statement on Form 1-A (the “Offering Statement”). The Offering Statement covers the contemplated |
|
| May 30, 2024 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 11.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the inclusion in this Amendment No. 2 to Form 1-A Registration Statement of Sharps Technology, Inc. filed under the Securities Act of 1933, of our report dated March 30, 2023, with respect to our audit of the consolidated financial statements of Sharps Technology Inc. as of December 31, 2022 and 2021, and for the y |
|
| May 30, 2024 |
Form 1-A/A (File No. 024-12438) PRELIMINARY OFFERING CIRCULAR DATED MAY 30, 2024 An offering statement pursuant to Regulation A relating to these securities has been filed with the Securities and Exchange Commission. |
|
| May 30, 2024 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| May 29, 2024 |
Exhibit 4.1 NOTICE TO INVESTORS THIS INVESTMENT INVOLVES A HIGH DEGREE OF RISK, SUITABLE ONLY FOR PERSONS WHO CAN BEAR THE ECONOMIC RISK FOR AN INDEFINITE PERIOD OF TIME AND WHO CAN AFFORD TO LOSE THEIR ENTIRE INVESTMENT. INVESTORS SHOULD FURTHER UNDERSTAND THAT THIS INVESTMENT IS ILLIQUID AND IS EXPECTED TO CONTINUE TO BE ILLIQUID FOR AN INDEFINITE PERIOD OF TIME. THE SECURITIES OFFERED HEREBY HA |
|
| May 29, 2024 |
Exhibit 99.1 |
|
| May 29, 2024 |
Independent Registered Public Accounting Firm’s Consent Exhibit 11.2 Independent Registered Public Accounting Firm’s Consent We consent to the inclusion in this Amendment No. 1 to Form 1-A of Sharps Technology, Inc. (the “Offering Statement”) filed under the Securities Act of 1933, of our report dated March 28, 2024, with respect to our audit of the consolidated financial statements of Sharps Technology Inc. as of December 31, 2023, and for the year th |
|
| May 29, 2024 |
Exhibit 12.1 May 21, 2024 Sharps Technology, Inc. 105 Maxess Road, Suite 124 Melville, NY 11747 Re: Offering Statement on Form 1-A Ladies and Gentlemen: We have acted as counsel to Sharps Technology, Inc. a Nevada corporation (the “Company”), in connection with the preparation and filing of an offering statement on Form 1-A (the “Offering Statement”). The Offering Statement covers the contemplated |
|
| May 29, 2024 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-269743 PROSPECTUS SUPPLEMENT NO. 1 Dated May 29, 2024 SHARPS TECHNOLOGY, INC. This prospectus supplement (“Supplement”) modifies, supersedes and supplements information contained in, and should be read in conjunction with, that certain Amendment No. 1 to Form S-1 Registration Statement, dated April 14, 2023 (the “Amended S-1”), of Sharps Techno |
|
| May 29, 2024 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 11.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the inclusion in this Amendment No. 1 to Form 1-A Registration Statement of Sharps Technology, Inc. filed under the Securities Act of 1933, of our report dated March 30, 2023, with respect to our audit of the consolidated financial statements of Sharps Technology Inc. as of December 31, 2022 and 2021, and for the y |
|
| May 29, 2024 |
PRELIMINARY OFFERING CIRCULAR DATED MAY 29, 2024 PRELIMINARY OFFERING CIRCULAR DATED MAY 29, 2024 An offering statement pursuant to Regulation A relating to these securities has been filed with the Securities and Exchange Commission. |
|
| May 28, 2024 |
Exhibit 99.1 Sharps Technology Positioned to Address Supply Chain Disruptions Resulting from Recent FDA Recalls, Warnings, and Tariffs on Chinese Manufactured Syringes Sharps CEO issues letter to shareholders on FDA actions and tariffs affecting Chinese syringes. The FDA began raising quality concerns over Chinese-manufactured syringes in November 2023, resulting in multiple recalls and warnings f |
|
| May 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 28, 2024 Sharps Technology, Inc. |
|
| May 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 24, 2024 Sharps Technology, Inc. |
|
| May 24, 2024 |
Exhibit 10.2 AMENDMENT NO. 1 TO ASSET PURCHASE AGREEMENT Amendment No. 1 to Asset Purchase Agreement dated May 20, 2024 (this “Amendment”), by and between Sharps Technology, Inc., a Nevada company (“Sharps”), Sharps Technology Acquisition Corp., a wholly owned subsidiary of Sharps (“Newco”) (Newco and Sharps are collectively referred to as the “Buyer”), and InjectEZ, LLC (the “Seller”). Sharps, Ne |
|
| May 24, 2024 |
Purchase Agreement dated May 6, 2024, by and between the Company and Nephron Pharmaceuticals, Inc. Exhibit 10.1 Nephron Purchase Agreement This Nephron Purchase Agreement (this “Agreement”) is made effective as of May 20, 2024 between Sharps Technology, Inc. a Nevada publicly traded company, having an address of 105 Maxess Road, Melville, NY 11747 or a wholly-owned subsidiary, (collectively the “Seller”), and NEPHRON SC, INC., a South Carolina limited liability company, having an address of 450 |
|
| May 21, 2024 |
Exhibit 12.1 May 21, 2024 Sharps Technology, Inc. 105 Maxess Road, Suite 124 Melville, NY 11747 Re: Offering Statement on Form 1-A Ladies and Gentlemen: We have acted as counsel to Sharps Technology, Inc. a Nevada corporation (the “Company”), in connection with the preparation and filing of an offering statement on Form 1-A (the “Offering Statement”). The Offering Statement covers the contemplated |
|
| May 21, 2024 |
AMENDMENT NO. 1 TO ASSET PURCHASE AGREEMENT Exhibit 6.3 AMENDMENT NO. 1 TO ASSET PURCHASE AGREEMENT Amendment No. 1 to Asset Purchase Agreement dated May 20, 2024 (this “Amendment”), by and between Sharps Technology, Inc., a Nevada company (“Sharps”), Sharps Technology Acquisition Corp., a wholly owned subsidiary of Sharps (“Newco”) (Newco and Sharps are collectively referred to as the “Buyer”), and InjectEZ, LLC (the “Seller”). Sharps, New |
|
| May 21, 2024 |
Exhibit 4.1 NOTICE TO INVESTORS THIS INVESTMENT INVOLVES A HIGH DEGREE OF RISK, SUITABLE ONLY FOR PERSONS WHO CAN BEAR THE ECONOMIC RISK FOR AN INDEFINITE PERIOD OF TIME AND WHO CAN AFFORD TO LOSE THEIR ENTIRE INVESTMENT. INVESTORS SHOULD FURTHER UNDERSTAND THAT THIS INVESTMENT IS ILLIQUID AND IS EXPECTED TO CONTINUE TO BE ILLIQUID FOR AN INDEFINITE PERIOD OF TIME. THE SECURITIES OFFERED HEREBY HA |
|
| May 21, 2024 |
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 11.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the inclusion in this Form 1-A Registration Statement of Sharps Technology, Inc. filed under the Securities Act of 1933, of our report dated March 30, 2023, with respect to our audit of the consolidated financial statements of Sharps Technology Inc. as of December 31, 2022 and 2021, and for the years then ended, or |
|
| May 21, 2024 |
Independent Registered Public Accounting Firm’s Consent Exhibit 11.2 Independent Registered Public Accounting Firm’s Consent We consent to the inclusion in this Offering Statement on Form 1-A of Sharps Technology, Inc. (the “Offering Statement”) filed under the Securities Act of 1933, of our report dated March 28, 2024, with respect to our audit of the consolidated financial statements of Sharps Technology Inc. as of December 31, 2023, and for the year |
|
| May 21, 2024 |
Exhibit 6.2 Nephron Purchase Agreement This Nephron Purchase Agreement (this “Agreement”) is made effective as of May 20, 2024 between Sharps Technology, Inc. a Nevada publicly traded company, having an address of 105 Maxess Road, Melville, NY 11747 or a wholly-owned subsidiary, (collectively the “Seller”), and NEPHRON SC, INC., a South Carolina limited liability company, having an address of 4500 |
|
| May 21, 2024 |
PRELIMINARY OFFERING CIRCULAR DATED MAY 21, 2024 An offering statement pursuant to Regulation A relating to these securities has been filed with the Securities and Exchange Commission. |
|
| May 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-41355 Sharps Technology, I |
|
| March 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-41355 Sharps Technology, Inc. (Exact name of registrant as specified in its |
|
| March 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 7, 2024 Sharps Technology, Inc. |
|
| March 8, 2024 |
Amendment to Cooperative Sales and Distribution Agreement Exhibit 10.2 AMENDMENT1 TO THE COOPERATIVE SALES AND DISTRIBUTION AGREEMENT This Amendment is made effective as of March 4, 2024, by and between: Roncadelle Operations s.r.l., a company formed and existing under the laws of Italy, having its registered office in Castel Mella (BS, Italy), Via Renolda 10, VAT code and registration number VAT-ID Number IT 04151620988, represented by Mr. Erik Ryckalts |
|
| March 8, 2024 |
Exhibit 10.3 |
|
| March 8, 2024 |
Exhibit 10.1 Cooperative Sales and Distribution Agreement This Cooperative Sales and Distribution Agreement (hereinafter the “Agreement”) is entered into as of this day 2024-03-01 (the “Effective Date”) by and between Roncadelle Operations s.r.l., a company formed and existing under the laws of Italy, having its registered office in Castel Mella (BS, Italy), Via Renolda 10, VAT code and registrati |
|
| March 7, 2024 |
Exhibit 99.1 Sharps Technology and Roncadelle Operations Sign Worldwide Sales and Distribution Agreement for their Innovative Portfolio of Safe Technology Drug Delivery Systems Sharps and Roncadelle are Joining Forces to Sell and Distribute their Securegard, SAFER, and Sologard Lines of Disposable Smart Safety Syringes and Expand their Market Reach Around the Globe Sharps Technology, Inc., (NASDAQ |
|
| March 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): March 7, 2024 Sharps Technology, Inc. |
|
| February 14, 2024 |
US82003F1012 / SHARPS TECHNOLOG / Walleye Capital LLC Passive Investment SC 13G 1 walleye-stss123123.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Sharps Technology, Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 82003F101 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate |
|
| January 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 16, 2024 Sharps Technology, Inc. |
|
| January 18, 2024 |
Exhibit 99.1 Sharps Technology Signs LOI with Roncadelle Operations Intended to Open Worldwide Sales and Distribution Opportunities for Safe Drug Delivery Systems Agreement would result in Sharps and Roncadelle Joining Forces to Access Global Healthcare Organizations Through More Than 30 Sales Partners worldwide Sharps Technology, Inc., (NASDAQ: “STSS” and “STSSW”), an innovative medical device an |
|
| January 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): January 18, 2024 Sharps Technology, Inc. |
|
| January 9, 2024 |
SC 13G 1 p24-0054sc13g.htm SHARPS TECHNOLOGY INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Sharps Technology Inc. (Name of Issuer) Common Stock, $0.0001 par value (Title of Class of Securities) 82003F101 (CUSIP Number) December 31, 2023 (Date of event which requires filing of this statement) Check the appropr |
|
| December 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 20, 2023 Sharps Technology, Inc. |
|
| December 22, 2023 |
Manning Elliot LLP Letter to SEC dated December 22, 2023 Exhibit 16.1 |
|
| December 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): December 19, 2023 Sharps Technology, Inc. |
|
| December 20, 2023 |
Sharps Technology, Inc. Amended and Restated 2023 Equity Incentive Plan Exhibit 10.1 SHARPS TECHNOLOGY, INC. AMENDED AND RESTATED 2023 EQUITY INCENTIVE PLAN 1. Purpose; Eligibility. 1.1 General Purpose. The name of this plan is the Sharps Technology, Inc., Amended and Restated 2023 Equity Incentive Plan (the “Plan”). The purposes of the Plan are to (a) enable Sharps Technology, Inc., a Nevada corporation (the “Company”), and any Affiliate to attract and retain the typ |
|
| November 14, 2023 |
Employment Agreement with Robert Hayes dated Novermber 10, 2023 Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT THIS EXECUTIVE EMPLOYMENT AGREEMENT (“Agreement”) is made and entered into on November 10, 2023 but shall be effective as of the 1st day of June 2023, by and between Sharps Technology, Inc., a Nevada Corporation (the “Company”) and Robert Hayes (the “Executive”) (together the Company and the Executive are the “Parties”) and supersedes and replaces any pr |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-41355 Sharps Technolog |
|
| November 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as Permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| October 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as Permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| October 24, 2023 |
Sharps Technology, Inc. October 24, 2023 Via EDGAR Division of Corporation Finance Office of Industrial Applications and Services U.S. Securities and Exchange Commission 100 F Street, NE Washington, D.C., 20549 Attention: Conlon Danberg Re: Sharps Technology, Inc. Registration Statement on Form S-1 Initially Filed on October 16, 2023 File No. 333-275011 Ms. Danberg: In accordance with Rule 461 of |
|
| October 16, 2023 |
Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Sharps Technology, Inc. (Exact name of registrant as specified in its charter) Nevada 3841 82-3751728 (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Id |
|
| October 16, 2023 |
Exhibit 107 Calculation of Filing Fee Table FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 (Form Type) Sharps Technology Inc. |
|
| October 3, 2023 |
Sharps Technology Announces Closing of $5.6 Million Registered Direct and Private Placement Exhibit 99.2 Sharps Technology Announces Closing of $5.6 Million Registered Direct and Private Placement NEW YORK, Sept. 29, 2023 (GLOBE NEWSWIRE) — Sharps Technology, Inc. (the “Company”) (NASDAQ: “STSS” and “STSSW”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, today announced the closing of its previously announced register |
|
| October 3, 2023 |
Form of the RD Securities Purchase Agreement, dated September 27, 2023 Exhibit 10.2 |
|
| October 3, 2023 |
Form of RD Pre-Funded Warrant (incorporated by reference to 8-K filed on October 3, 2023) Exhibit 10.6 PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK SHARPS TECHNOLOGY, INC. Warrant Shares: [] Initial Exercise Date: [], 2023 Issue Date: [], 2023 THIS PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK (the “Warrant”) certifies that, for value received, [] or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, |
|
| October 3, 2023 |
Exhibit 10.4 |
|
| October 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 27, 2023 Sharps Technology, Inc. |
|
| October 3, 2023 |
Form of PIPE Pre-Funded Warrant (incorporated by reference to 8-K filed on October 3, 2023) Exhibit 10.7 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| October 3, 2023 |
Exhibit 10.3 |
|
| October 3, 2023 |
Form of Warrant (incorporated by reference to 8-K filed on October 3, 2023) Exhibit 10.5 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGIST |
|
| October 3, 2023 |
Exhibit 10.1 |
|
| October 3, 2023 |
Exhibit 99.1 Sharps Technology Announces $5.6 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules NEW YORK, Sept. 27, 2023 (GLOBE NEWSWIRE) - Sharps Technology, Inc. (the “Company”) (NASDAQ: “STSS” and “STSSW”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, today announced that it has entered |
|
| September 29, 2023 |
3,618,521 Shares of Common Stock Pre-Funded Warrants to Purchase 800,000 Shares of Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-274146 PROSPECTUS SUPPLEMENT (To Prospectus dated September 5, 2023) 3,618,521 Shares of Common Stock Pre-Funded Warrants to Purchase 800,000 Shares of Common Stock We are offering (a) 3,618,521 shares of our common stock, $0.001 par value per share, and (b) prefunded warrants to purchase up to 800,000 shares of common stock, at an exercise pri |
